1. Yang DD, Nguyen PL, D’Amico AV. Elective Pelvic Lymph Node Radiation in Prostate Cancer Revisited. J Clin Oncol Off J Am Soc Clin Oncol. 2021 Jun 4;JCO2100621.
2. National Comprehensive Cancer Network. Prostate Version 2.2021 [Internet]. 2021 [cited 2021 Jun 17]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
3. Professionals S-O. EAU Guidelines: Prostate Cancer [Internet]. Uroweb. [cited 2021 Jun 17]. Available from: https://uroweb.org/guideline/prostate-cancer/
4. Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G, et al. Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. J Clin Oncol. 2021 Apr 10;39(11):1234–42.
5. Murthy V, Maitre P, Bhatia J, Kannan S, Krishnatry R, Prakash G, et al. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020 Apr;145:71–80.
6. Dearnaley D, Griffin CL, Lewis R, Mayles P, Mayles H, Naismith OF, et al. Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL). Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):605–17.
7. Wilkins A, Naismith O, Brand D, Fernandez K, Hall E, Dearnaley D, et al. Derivation of Dose/Volume Constraints for the Anorectum from Clinician- and Patient-Reported Outcomes in the CHHiP Trial of Radiation Therapy Fractionation. Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):928–38.
8. Schaake W, van der Schaaf A, van Dijk LV, Bongaerts AHH, van den Bergh ACM, Langendijk JA. Normal tissue complication probability (NTCP) models for late rectal bleeding, stool frequency and fecal incontinence after radiotherapy in prostate cancer patients. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2016 Jun;119(3):381–7.
9. Schaake W, van der Schaaf A, van Dijk LV, van den Bergh ACM, Langendijk JA. Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients. PLoS ONE [Internet]. 2018 Jul 17 [cited 2021 Jun 17];13(7). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049922/
10. Kamran SC, Light JO, Efstathiou JA. Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care. Prostate Cancer Prostatic Dis. 2019 Dec;22(4):509–21.
11. Wisenbaugh ES, Andrews PE, Ferrigni RG, Schild SE, Keole SR, Wong WW, et al. Proton Beam Therapy for Localized Prostate Cancer 101: Basics, Controversies, and Facts. Rev Urol. 2014;16(2):67–75.
12. Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, et al. Radiotherapy treatment of early stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):444–53.
13. Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):744–51.
14. Zhang X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, et al. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):620–9.
15. Efstathiou J. Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Intermediate Risk Prostate Cancer [Internet]. clinicaltrials.gov; 2020 Sep [cited 2021 Jun 15]. Report No.: NCT01617161. Available from: https://clinicaltrials.gov/ct2/show/NCT01617161
16. University of Florida. A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer [Internet]. clinicaltrials.gov; 2021 Jan [cited 2021 Jun 15]. Report No.: NCT03561220. Available from: https://clinicaltrials.gov/ct2/show/NCT03561220
17. Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013 Jun;107(3):267–73.
18. Langendijk JA, Boersma LJ, Rasch CRN, van Vulpen M, Reitsma JB, van der Schaaf A, et al. Clinical Trial Strategies to Compare Protons With Photons. Semin Radiat Oncol. 2018 Apr;28(2):79–87.
19. Smeenk RJ, Hoffmann AL, Hopman WPM, van Lin ENJT, Kaanders JHAM. Dose-effect relationships for individual pelvic floor muscles and anorectal complaints after prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):636–44.
20. Fowler JF. 21 years of Biologically Effective Dose. Br J Radiol. 2010 Jul;83(991):554–68.
21. Haque W, Butler EB, Teh BS. Toxicity of pelvic nodal radiation for localized prostate cancer. Ann Transl Med [Internet]. 2019 Dec [cited 2021 Jun 17];7(Suppl 8). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976416/
22. Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1504–15.
23. Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol Off J Am Soc Clin Oncol. 2007 Dec 1;25(34):5366–73.
24. Parry MG, Sujenthiran A, Cowling TE, Nossiter J, Cathcart P, Clarke NW, et al. Treatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based Study. J Clin Oncol Off J Am Soc Clin Oncol. 2019 Jul 20;37(21):1828–35.
25. Bryant C, Smith TL, Henderson RH, Hoppe BS, Mendenhall WM, Nichols RC, et al. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):422–34.
26. Chera BS, Vargas C, Morris CG, Louis D, Flampouri S, Yeung D, et al. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):994–1002.
27. Whitaker TJ, Routman DM, Schultz H, Harmsen WS, Corbin KS, Wong WW, et al. IMPT versus VMAT for Pelvic Nodal Irradiation in Prostate Cancer: A Dosimetric Comparison. Int J Part Ther. 2019;5(3):11–23.
28. Teh BS, McGary JE, Dong L, Mai W-Y, Carpenter LS, Lu HH, et al. The use of rectal balloon during the delivery of intensity modulated radiotherapy (IMRT) for prostate cancer: more than just a prostate gland immobilization device? Cancer J Sudbury Mass. 2002 Dec;8(6):476–83.
29. Landoni V, Fiorino C, Cozzarini C, Sanguineti G, Valdagni R, Rancati T. Predicting toxicity in radiotherapy for prostate cancer. Phys Medica PM Int J Devoted Appl Phys Med Biol Off J Ital Assoc Biomed Phys AIFB. 2016 Mar;32(3):521–32.
30. Pedersen J, Liang X, Casares-Magaz O, Bryant C, Mendenhall N, Li Z, et al. Multivariate normal tissue complication probability models for rectal and bladder morbidity in prostate cancer patients treated with proton therapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020 Dec;153:279–88.
31. Schreiber D, Chen S-C, Rineer J, Worth M, Telivala T, Schwartz D. Assessment of risk of late rectal bleeding for patients with prostate cancer started on anticoagulation before or after radiation treatment. Anticancer Res. 2014 Dec;34(12):7367–72.
32. Sanguedolce F, Sancho Pardo G, Mercadé Sanchez A, Balaña Lucena J, Pisano F, Cortez JC, et al. Radiation-induced haemorrhagic cystitis after prostate cancer radiotherapy: factors associated to hospitalization and treatment strategies. Prostate Int. 2021 Mar;9(1):48–53.
33. Tambas M, Steenbakkers RJHM, van der Laan HP, Wolters AM, Kierkels RGJ, Scandurra D, et al. First experience with model-based selection of head and neck cancer patients for proton therapy. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020 Oct;151:206–13.
34. Rapporten [Internet]. Dutch Association for Radiotherapy and Oncology. [cited 2021 Jul 9]. Available from: https://nvro.nl/publicaties/rapporten
35. Marteinsdottir M, Paganetti H. Applying a variable relative biological effectiveness (RBE) might affect the analysis of clinical trials comparing photon and proton therapy for prostate cancer. Phys Med Biol. 2019 Jun 5;64(11):115027.
36. Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015 Jan 6;162(1):W1-73.